ACT Biotech

About ACT Biotech

ACT Biotech, Inc. operated as a biopharmaceutical firm with a clear focus on the development and subsequent commercialization of targeted oral cancer therapeutics. Founded in 2008 and based in San Francisco, the company assembled a pipeline of small molecule kinase inhibitors aimed at various cancers. A significant portion of its early-stage and clinical oncology portfolio was acquired through licenses from Bayer HealthCare, a transaction that occurred in May 2008. The company's business model centered on advancing these assets through clinical trials to address unmet needs in oncology.

One of its principal assets was Telatinib, an oral kinase inhibitor intended for the first-line treatment of advanced gastric cancer. This drug candidate received Orphan Drug status from the U.S. Food and Drug Administration, a designation that provides incentives to support the development of drugs for rare diseases. Another key pipeline product was ACTB1003, an oral kinase inhibitor designed to inhibit cancer cell growth by targeting the FGF receptor family and also inducing apoptosis through downstream kinase inhibition. The company's strategy also included developing an oral Aurora A and B kinase inhibitor and an ABL tyrosine kinase inhibitor. Throughout its operational history, ACT Biotech successfully raised capital to fund its research and development, securing $9.07 million over four funding rounds, with investors including NGN Capital and Sobera Capital.

In January 2014, the company's oncology assets were acquired by Eddingpharm. Following this transaction, ACT Biotech appears to have ceased independent operations, with PitchBook listing the company as 'Out of Business' as of September 2015. One of its co-founders, Ali Fattaey, transitioned to a role at Curis in February 2013, prior to the asset acquisition.